Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Shares Shorted: Short Interest Up 4,905.1% in October

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) saw a large increase in short interest in the month of October. As of October 15th, there was short interest totaling 919,936 shares, an increase of 4,905.1% from the September 30th total of 18,380 shares. Currently, 89.7% of the shares of the stock are sold short. Based on an average trading volume of 7,171,805 shares, the short-interest ratio is presently 0.1 days.

Biodexa Pharmaceuticals Trading Up 9.0%

BDRX traded up $0.30 during trading on Monday, reaching $3.69. The company had a trading volume of 40,694 shares, compared to its average volume of 228,197. The firm’s 50-day simple moving average is $0.77 and its 200 day simple moving average is $2.12. Biodexa Pharmaceuticals has a 12-month low of $2.70 and a 12-month high of $357.60.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Biodexa Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, October 14th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals plc, formerly known as Midatech Pharma plc, is a biopharmaceutical company focused on developing medicines for diseases with significant unmet medical needs. The company’s work has centered on oncology, rare diseases and conditions that are difficult to treat with conventional drug-delivery methods.

Biodexa’s development programs have included MTX110, a proprietary aqueous formulation of panobinostat being investigated for direct administration into brain tumors, including diffuse intrinsic pontine glioma.